Ascletis Pharma Stock Return On Equity
| ASCLF Stock | USD 0.24 0.00 0.00% |
Ascletis Pharma fundamentals help investors to digest information that contributes to Ascletis Pharma's financial success or failures. It also enables traders to predict the movement of Ascletis Pink Sheet. The fundamental analysis module provides a way to measure Ascletis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascletis Pharma pink sheet.
Ascletis |
Ascletis Pharma Company Return On Equity Analysis
Ascletis Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Ascletis Pharma Return On Equity | -0.0632 |
Most of Ascletis Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascletis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Ascletis Pharma has a Return On Equity of -0.0632. This is 99.74% lower than that of the Healthcare sector and 99.83% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 79.61% lower than that of the firm.
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Ascletis Fundamentals
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 116.15 M | |||
| Shares Outstanding | 1.09 B | |||
| Shares Owned By Insiders | 67.02 % | |||
| Shares Owned By Institutions | 1.94 % | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 7.61 X | |||
| Revenue | 76.88 M | |||
| Gross Profit | 39.17 M | |||
| EBITDA | (169.35 M) | |||
| Net Income | (199.02 M) | |||
| Cash And Equivalents | 2.5 B | |||
| Cash Per Share | 2.28 X | |||
| Total Debt | 2.75 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 28.93 X | |||
| Book Value Per Share | 2.50 X | |||
| Cash Flow From Operations | (146.93 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 315 | |||
| Beta | 0.81 | |||
| Market Capitalization | 672.93 M | |||
| Total Asset | 2.83 B | |||
| Net Asset | 2.83 B |
About Ascletis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascletis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascletis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascletis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.